Bioelectronics Corp (BIEL) 0.0006 $BIEL
BioElectronics CEO Andrew Whelan to Be Interviewed Live Thursday on New Equity Network Talk Radio Show
ACCESSWIRE - Thu May 14, 2:05PM CDT
Interview Scheduled at 10:30am CT on the New Equity Network Radio Show, Hosted by Michael Yorba
BioElectronics Expands Medical and OTC Distribution
PR Newswire - Tue Mar 24, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices, announced today that it has signed Medikon, one of the country's leading medical suppliers as the distributor for RecoveryRx® Therapy for post-operative and chronic wound care, ActiPatch® Musculoskeletal Therapy, Allay® Menstrual Pain Therapy and Smart Insole(TM) in Turkey.
BioElectronics Executive Vice President Dr. Deepak Kotak Interviewed on CEOLIVE.TV - Explains the Changing Paradigm of Chronic Pain
PR Newswire - Mon Feb 09, 7:30AM CST
BioElectronics Corporation (OTC: BIEL), the maker of an industry leading family of bioelectric pain therapy devices, said today that its Executive Vice President, Dr. Deepak Kotak, was interviewed by CEOLIVE.TV as part of its Executive Interview Series.
BioElectronics' ActiPatch® Actual-Use Survey Finds 90% Have Excellent Chronic Pain Management and 88% had a Decrease in Opioid Use
PR Newswire - Wed Feb 04, 7:30AM CST
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released analysis of its ongoing and second long term follow up survey of customers in the United Kingdom and Ireland who are managing chronic pain with ActiPatch® Therapy, and reducing their dependence on systemic pain drugs. The study of more than 1,300 consumers looked at their chronic pain management, quality of life, pain medication use, and purchasing extent of ActiPatch®.
BioElectronics Announces B. Braun as the UK Distributor for Pain Device in Orthopaedics
PR Newswire - Wed Jan 14, 7:30AM CST
BioElectronics Corporation, USA, (OTC Pink: BIEL), today announced that B. Braun Medical Ltd is the exclusive UK distributor of the BioElectronics' RecoveryRx® pain device in orthopaedics and trauma.
UK Fibromyalgia Sufferers Petition the National Health Service to Integrate and Pay for BioElectronics' ActiPatch® Therapy
PR Newswire - Wed Nov 26, 7:30AM CST
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer and healthcare medical devices announced today that Pifflers United Chronic and Invisible Illnesses Support Community, www.facebook.com/PifflersUnited, is petitioning the United Kingdom's NHS' National Institute for Health & Care Excellence (NICE) for new guidelines for effective Fibromyalgia pain management.
BioElectronics Changing Chronic Pain Treatments
PR Newswire - Wed Nov 05, 7:30AM CST
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer and healthcare medical devices announced today that its Executive Vice President, Dr. Deepak Kotak has been invited to present BioElectronics' innovative chronic pain therapy at the OTC Pharma Asia Conference, http://www.otcpharmaasia.com/ on Tuesday, March 3, 2015 in Singapore.
Chronic Pain Sufferers Confirm BioElectronics' ActiPatch® Therapy Provides Life Changing Pain Relief
PR Newswire - Mon Oct 27, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released updated results of its "Try It and Tell Us" 7-day ActiPatch sample program for United Kingdom and Ireland residents who were surveyed about their experience. The data now includes responses from 856 consumers suffering from chronic pain caused by a number of musculoskeletal conditions.
BioElectronics Analyst Brief: Beyond the Traditional Therapies by Small Cap Traders
PR Newswire - Mon Oct 20, 6:30AM CDT
There can be no doubt that the market for pain relief products will continue to grow, regardless of the economic climate. As the massive baby boomer population ages their aches and pains will follow them and the affordable Care act should make more funding available to spend on pain relief products. As the population becomes more health aware, the use of oral pain medications like aspirin is being questioned and too often topical analgesics don't provide the desired effect. Electronic stimulation of inflamed tissue seems to be a viable alternative that has yet to be fully embraced in the medical community or the general population.
Facebook Survey Shows UK Consumers Experience 52% Reduction in Intractable Chronic Pain with ActiPatch® Therapy in Musculoskeletal Pain
PR Newswire - Tue Aug 26, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released the updated results of its "Try It and Tell Us" 7-day ActiPatch sample program for United Kingdom and Ireland residents who were surveyed about their experience. Overall results for chronic musculoskeletal pain showed a 77% efficacy to ActiPatch Therapy with an average pain decrease of 52%. Visit www.bielcorp.com/clinical-evidence/musculoskeletal-pain to see the 430 consumer responses and www.facebook.com/ActiPatch to view what people in the UK and Ireland are saying about the products.
BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live
PR Newswire - Mon Aug 18, 6:20PM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices said that its EVP Dr. Deepak Kotak was interviewed by CEOLIVE.TV as part of its Executive Interview Series.
BioElectronics President Letter to Shareholders
PR Newswire - Mon Aug 04, 7:30AM CDT
The following is a letter from the President of BioElectronics Corporation (OTC Pink: BIEL) to shareholders:
BioElectronics "Try It and Tell Us" Facebook Social Media Program Builds Momentum and User Testimonials
PR Newswire - Mon Jun 30, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today announced positive early feedback from its "Try It and Tell Us" social media program in the United Kingdom that has attracted thousands of followers. The company's Facebook-based program offers U.K. and Irish consumers free trial devices, delivering a week of therapy, and then surveys them about their experience including self-reported pain personal experience.
BioElectronics CEO Andrew Whelan to Be Interviewed Live Thursday on New Equity Network Talk Radio Show
ACCESSWIRE - Thu May 14, 2:05PM CDT
Interview Scheduled at 10:30am CT on the New Equity Network Radio Show, Hosted by Michael Yorba
BioElectronics Expands Medical and OTC Distribution
PR Newswire - Tue Mar 24, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices, announced today that it has signed Medikon, one of the country's leading medical suppliers as the distributor for RecoveryRx® Therapy for post-operative and chronic wound care, ActiPatch® Musculoskeletal Therapy, Allay® Menstrual Pain Therapy and Smart Insole(TM) in Turkey.
BioElectronics Executive Vice President Dr. Deepak Kotak Interviewed on CEOLIVE.TV - Explains the Changing Paradigm of Chronic Pain
PR Newswire - Mon Feb 09, 7:30AM CST
BioElectronics Corporation (OTC: BIEL), the maker of an industry leading family of bioelectric pain therapy devices, said today that its Executive Vice President, Dr. Deepak Kotak, was interviewed by CEOLIVE.TV as part of its Executive Interview Series.
BioElectronics' ActiPatch® Actual-Use Survey Finds 90% Have Excellent Chronic Pain Management and 88% had a Decrease in Opioid Use
PR Newswire - Wed Feb 04, 7:30AM CST
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released analysis of its ongoing and second long term follow up survey of customers in the United Kingdom and Ireland who are managing chronic pain with ActiPatch® Therapy, and reducing their dependence on systemic pain drugs. The study of more than 1,300 consumers looked at their chronic pain management, quality of life, pain medication use, and purchasing extent of ActiPatch®.
BioElectronics Announces B. Braun as the UK Distributor for Pain Device in Orthopaedics
PR Newswire - Wed Jan 14, 7:30AM CST
BioElectronics Corporation, USA, (OTC Pink: BIEL), today announced that B. Braun Medical Ltd is the exclusive UK distributor of the BioElectronics' RecoveryRx® pain device in orthopaedics and trauma.
UK Fibromyalgia Sufferers Petition the National Health Service to Integrate and Pay for BioElectronics' ActiPatch® Therapy
PR Newswire - Wed Nov 26, 7:30AM CST
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer and healthcare medical devices announced today that Pifflers United Chronic and Invisible Illnesses Support Community, www.facebook.com/PifflersUnited, is petitioning the United Kingdom's NHS' National Institute for Health & Care Excellence (NICE) for new guidelines for effective Fibromyalgia pain management.
BioElectronics Changing Chronic Pain Treatments
PR Newswire - Wed Nov 05, 7:30AM CST
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer and healthcare medical devices announced today that its Executive Vice President, Dr. Deepak Kotak has been invited to present BioElectronics' innovative chronic pain therapy at the OTC Pharma Asia Conference, http://www.otcpharmaasia.com/ on Tuesday, March 3, 2015 in Singapore.
Chronic Pain Sufferers Confirm BioElectronics' ActiPatch® Therapy Provides Life Changing Pain Relief
PR Newswire - Mon Oct 27, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released updated results of its "Try It and Tell Us" 7-day ActiPatch sample program for United Kingdom and Ireland residents who were surveyed about their experience. The data now includes responses from 856 consumers suffering from chronic pain caused by a number of musculoskeletal conditions.
BioElectronics Analyst Brief: Beyond the Traditional Therapies by Small Cap Traders
PR Newswire - Mon Oct 20, 6:30AM CDT
There can be no doubt that the market for pain relief products will continue to grow, regardless of the economic climate. As the massive baby boomer population ages their aches and pains will follow them and the affordable Care act should make more funding available to spend on pain relief products. As the population becomes more health aware, the use of oral pain medications like aspirin is being questioned and too often topical analgesics don't provide the desired effect. Electronic stimulation of inflamed tissue seems to be a viable alternative that has yet to be fully embraced in the medical community or the general population.
Facebook Survey Shows UK Consumers Experience 52% Reduction in Intractable Chronic Pain with ActiPatch® Therapy in Musculoskeletal Pain
PR Newswire - Tue Aug 26, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released the updated results of its "Try It and Tell Us" 7-day ActiPatch sample program for United Kingdom and Ireland residents who were surveyed about their experience. Overall results for chronic musculoskeletal pain showed a 77% efficacy to ActiPatch Therapy with an average pain decrease of 52%. Visit www.bielcorp.com/clinical-evidence/musculoskeletal-pain to see the 430 consumer responses and www.facebook.com/ActiPatch to view what people in the UK and Ireland are saying about the products.
BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live
PR Newswire - Mon Aug 18, 6:20PM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices said that its EVP Dr. Deepak Kotak was interviewed by CEOLIVE.TV as part of its Executive Interview Series.
BioElectronics President Letter to Shareholders
PR Newswire - Mon Aug 04, 7:30AM CDT
The following is a letter from the President of BioElectronics Corporation (OTC Pink: BIEL) to shareholders:
BioElectronics "Try It and Tell Us" Facebook Social Media Program Builds Momentum and User Testimonials
PR Newswire - Mon Jun 30, 7:30AM CDT
BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today announced positive early feedback from its "Try It and Tell Us" social media program in the United Kingdom that has attracted thousands of followers. The company's Facebook-based program offers U.K. and Irish consumers free trial devices, delivering a week of therapy, and then surveys them about their experience including self-reported pain personal experience.
